Lifecore Biomedical, Inc. (LFCR)
(Real Time Quote from BATS)
$7.44 USD
+0.45 (6.44%)
Updated Aug 4, 2025 03:30 PM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
LFCR 7.44 +0.45(6.44%)
Will LFCR be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for LFCR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for LFCR
Lifecore Biomedical (LFCR) Reports Q3 Loss, Misses Revenue Estimates
Dare Bioscience, Inc. (DARE) Reports Q4 Loss, Misses Revenue Estimates
LFCR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Lifecore Biomedical (LFCR) Reports Q2 Loss, Tops Revenue Estimates
Other News for LFCR
Lifecore Biomedical to Report Fourth Quarter and Fiscal Year 2025 Financial Results on August ...
Laughing Water Capital Q2 2025 Letter
Lifecore Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | LFCR Stock News
Stock Picks From Seeking Alpha's June 2025 New Analysts
Lifecore Biomedical: Inflecting Financials Over Next 3 Years